Literature DB >> 3370018

High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study.

R D Abbott1, P W Wilson, W B Kannel, W P Castelli.   

Abstract

The relation between high density lipoprotein cholesterol (HDL-C) and the development of myocardial infarction was examined in 2425 subjects, aged 50 to 79 years, who were enrolled in the Framingham Study from 1969 to 1971. After 12 years of follow-up, men in the bottom three quartiles of HDL-C (less than or equal to 52 mg/dl) experienced a 60% to 70% excess of myocardial infarction as compared to men whose HDL-C levels were higher (p less than 0.05). The effect of HDL-C was especially strong in women. In separate comparisons to the 4th quartile of HDL-C (greater than or equal to 67 mg/dl), the risk of myocardial infarction increased from a fourfold excess in the adjacent 3rd quartile (56 to 66 mg/dl, p less than 0.01) to a nearly sixfold excess in the 1st quartile (less than or equal to 46 mg/dl, p less than 0.001). These results persisted after adjusting for age and other risk factors. In addition, a significant effect of HDL-C remained in subjects who had the lowest concentrations of total cholesterol (less than or equal to 192 mg/dl in men and 211 mg/dl in women) in which 29% had levels of HDL-C (less than or equal to 36 mg/dl in men and 46 mg/dl in women) that were associated with a marked elevation in the incidence of myocardial infarction. We conclude that screening for total cholesterol alone in men and women aged 50 and older may not adequately identify the coronary candidate.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3370018     DOI: 10.1161/01.atv.8.3.207

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  68 in total

Review 1.  Impact of dyslipidaemia. Lessons from clinical trials.

Authors:  W V Brown
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

Review 2.  Risk factors for cardiovascular disease and hormone therapy in women.

Authors:  P Collins
Journal:  Heart       Date:  2006-05       Impact factor: 5.994

Review 3.  Management of lipid disorders in the elderly.

Authors:  D A Playford; G F Watts
Journal:  Drugs Aging       Date:  1997-06       Impact factor: 3.923

4.  High-density lipoprotein subfractions in normolipidemic individuals without clinical atherosclerosis lipoprotein subfractions in an adult population.

Authors:  Fabio L Sodré; Vera S Castanho; Lucia N Castilho; Silvia de Barros-Mazon; Eliana C de Faria
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

5.  Limitations of a Cardiac Risk (QRISK2) Calculator in Patients with High Density Lipoprotein (HDL).

Authors:  Jatinder S Minhas; Prashanth Patel; Pankaj K Gupta
Journal:  High Blood Press Cardiovasc Prev       Date:  2016-02-23

6.  The relationship between physical fitness and coronary risk factor profiles in Japanese women.

Authors:  T Takamiya; T Shimomitsu; Y Odagiri; Y Ohya; A Sakamoto; T Katsumura; N Murase; M Naka; J Kajiyama
Journal:  Environ Health Prev Med       Date:  2000-04       Impact factor: 3.674

7.  Clinical efficacy of the direct assay method using polymers for serum high density lipoprotein cholesterol.

Authors:  K Shirai; T Nema; Y Hiroh; Y Itoh; Y Miyashita; H Watanabe
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

8.  Kinetic parameters for high density lipoprotein apoprotein AI and cholesteryl ester transport in the hamster.

Authors:  L A Woollett; D K Spady
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

9.  Water chlorination and lipo- and apolipoproteins: the relationship in elderly white women of western Pennsylvania.

Authors:  T J Riley; J A Cauley; P A Murphy
Journal:  Am J Public Health       Date:  1995-04       Impact factor: 9.308

10.  Validation of reported physical activity for cholesterol control using two different physical activity instruments.

Authors:  Amy Z Fan; Sandra A Ham; Shravani Reddy Muppidi; Ali H Mokdad
Journal:  Vasc Health Risk Manag       Date:  2009-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.